{"id":2230,"date":"2026-06-10T02:00:00","date_gmt":"2026-06-10T05:00:00","guid":{"rendered":"https:\/\/sevenresiduosaude.com.br\/blog\/?p=2230"},"modified":"2026-06-10T02:00:00","modified_gmt":"2026-06-10T05:00:00","slug":"rss-clinica-medicina-pneumologia-dpoc-asma-ild-cpap-bipap-oxigenoterapia-transplante-pulmonar","status":"publish","type":"post","link":"https:\/\/sevenresiduosaude.com.br\/blog\/rss-clinica-medicina-pneumologia-dpoc-asma-ild-cpap-bipap-oxigenoterapia-transplante-pulmonar\/","title":{"rendered":"RSS pneumo: DPOC, asma, ILD, CPAP, TX pulm"},"content":{"rendered":"

A regula\u00e7\u00e3o brasileira de RSS \u00e9 frequentemente subaproveitada por gestores de cl\u00ednicas de pneumologia que reduzem RSS a descarte de m\u00e1scara e cateter<\/strong>. Em 2026, h\u00e1 um cen\u00e1rio desafiador \u2014 cl\u00ednicas de pneumologia<\/strong> + DPOC GOLD 1-4 + ABCD + biol\u00f3gicos novos<\/strong> + asma grave T2-high biologic + dupilumab + tezepelumab + benralizumab + mepolizumab + omalizumab<\/strong> + ILD interstitial lung disease + IPF idiopathic pulmonary fibrosis + nintedanib + pirfenidona<\/strong> + SAOS apneia obstrutiva + CPAP + BiPAP + ASV + Inspire device<\/strong> + oxigenioterapia domiciliar + TX pulmonar<\/strong> geram fluxos heterog\u00eaneos de RSS Grupo A1 (sangue venoso PFP fun\u00e7\u00e3o pulmonar + gasometria arterial) + Grupo A2 (secre\u00e7\u00e3o respirat\u00f3ria + escarro induzido + lavado bronco-alveolar BAL + bi\u00f3psia transbr\u00f4nquica) + Grupo B (broncodilatador SABA+LABA + ICS+LABA combina\u00e7\u00e3o Symbicort+Seretide+Trelegy + biol\u00f3gico anti-IgE+anti-IL-5+anti-TSLP Lista B\/C5 + nintedanib Ofev+pirfenidona Esbriet anti-fibr\u00f3tico + tacrolimus+ciclosporina+everolimus+sirolimus p\u00f3s-TX) + Grupo E (perfuro Vacutainer + cateter + agulha BAL + fibrosc\u00f3pio reus\u00e1vel). A consequ\u00eancia \u00e9 a pr\u00e1tica de cl\u00ednicas que otimizam apenas para sangue venoso<\/strong> + ignoram especificidades pneumol\u00f3gicas + biol\u00f3gicos T2-high + IPF anti-fibr\u00f3tico<\/strong> + subdimensionam CPAP\/BiPAP descarte<\/strong> + perdem rastreabilidade GOLD\/T2\/UIP<\/strong>. A realidade \u00e9 exatamente o oposto. RSS pneumo opera em 5 fluxos pneumol\u00f3gicos<\/strong> \u2014 DPOC GOLD (1-4 + ABCD + Symbicort\/Seretide\/Trelegy + roflumilast Daxas), asma T2-high (omalizumab Xolair anti-IgE + mepolizumab Nucala anti-IL-5 + benralizumab Fasenra anti-IL-5R + reslizumab Cinqair + dupilumab Dupixent anti-IL-4R\u03b1 + tezepelumab Tezspire anti-TSLP), ILD\/IPF (nintedanib Ofev + pirfenidona Esbriet + UIP usual interstitial pneumonia + NSIP + COP + sarcoidosis + connective tissue disease ILD), SAOS+CPAP+BiPAP (ResMed AirSense + Philips DreamStation + Inspire upper airway stimulation + ASV adaptive servo-ventilation), TX pulmonar (LAS Lung Allocation Score + bilateral sequential + single-lung + cystic fibrosis + IPF + DPOC end-stage + bridge ECMO).<\/p>\n

Para o gestor que opera ou planeja cl\u00ednica de pneumologia, \u00e9 fundamental dimensionar RSS espec\u00edfico desde o in\u00edcio.<\/p>\n

Os 5 fluxos pneumol\u00f3gicos<\/h2>\n

Em uma opera\u00e7\u00e3o de qualquer porte, o RSS pneumo tem 5 fluxos.<\/p>\n\n\n\n\n\n\n\n\n\n
Fluxo<\/th>\nVolume<\/th>\nFrequ\u00eancia<\/th>\nParticularidade<\/th>\n<\/tr>\n<\/thead>\n
DPOC GOLD 1-4<\/td>\n4-12 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nSymbicort+roflumilast<\/td>\n<\/tr>\n
Asma T2-high biol\u00f3gico<\/td>\n2-6 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nAnti-IgE+IL-5+TSLP<\/td>\n<\/tr>\n
ILD\/IPF anti-fibr\u00f3tico<\/td>\n1,5-4 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nNintedanib+pirfenid<\/td>\n<\/tr>\n
SAOS CPAP+Inspire<\/td>\n3-9 kg\/dia<\/td>\nDi\u00e1ria<\/td>\nResMed+Philips+Inspire<\/td>\n<\/tr>\n
TX pulmonar+ECMO<\/td>\n1-3 kg\/dia<\/td>\nP\u00f3s-procedimento<\/td>\nLAS+bilat+ECMO<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

A soma t\u00edpica \u00e9 11,5-34 kg\/dia<\/strong> em cl\u00ednica pneumo m\u00e9dia porte.<\/p>\n

DPOC GOLD 1-4 + asma T2-high biol\u00f3gico: o est\u00e1gio obstrutivo<\/h2>\n

A primeira camada \u00e9 DPOC+asma. Padr\u00e3o setorial inclui (a) DPOC GOLD 2026<\/strong> com FEV1 % previsto GOLD 1\u226580%\/2 50-79%\/3 30-49%\/4<30% + ABCD avalia\u00e7\u00e3o sintoma+exacerba\u00e7\u00e3o + LAMA tiotropium Spiriva+umeclidinium Incruse+glicopirr\u00f4nio Seebri + LABA salmeterol+formoterol+vilanterol+olodaterol + ICS budesonida+fluticasona+mometasona + triple inhaler Trelegy Ellipta + Symbicort + Breztri Aerosphere + Trimbow + roflumilast Daxas Lista C5; (b) asma T2-high biological<\/strong> com omalizumab Xolair Genentech anti-IgE 75-375mg SC q2-4w + mepolizumab Nucala GSK anti-IL-5 100mg SC q4w + benralizumab Fasenra AstraZeneca anti-IL-5R\u03b1 30mg SC q4-8w + reslizumab Cinqair Teva anti-IL-5 IV + dupilumab Dupixent Sanofi\/Regeneron anti-IL-4R\u03b1 200-300mg SC q2w + tezepelumab Tezspire AstraZeneca\/Amgen anti-TSLP 210mg SC q4w + itepekimab anti-IL-33; (c) biomarker<\/strong> eosinophil >300 cells\/\u03bcL + FeNO Fractional exhaled Nitric Oxide >25 ppb + IgE total + IgE espec\u00edfico + periostin; (d) PFP fun\u00e7\u00e3o pulmonar<\/strong> com espirometria pr\u00e9+p\u00f3s-broncodilatador + DLCO Diffusing Lung Carbon monoxide + pletismografia volume residual + 6MWT 6-minute walk test + cardiopulmonary exercise testing CPET; (e) descarte DPOC+asma<\/strong> com saco amarelo+vermelho + identifica\u00e7\u00e3o Lista B inalador+Lista C5 biol\u00f3gico+CID J44\/J45 + lacre.<\/p>\n

Cl\u00ednica com DPOC+asma T2 madura escala redu\u00e7\u00e3o exacerba\u00e7\u00e3o 50-70%<\/strong> + previne hospitaliza\u00e7\u00e3o<\/strong> + reduz depend\u00eancia ICS oral<\/strong>. Como discutimos no post sobre hospital especializado<\/a>, DPOC+asma \u00e9 base.<\/p>\n

ILD + IPF + nintedanib + pirfenidona + SAOS CPAP\/BiPAP\/Inspire: o est\u00e1gio fibrosante+SAOS<\/h2>\n

A segunda camada \u00e9 ILD+SAOS. Padr\u00e3o setorial inclui (a) ILD interstitial lung disease<\/strong> com IPF idiopathic 35% + NSIP non-specific + COP cryptogenic + sarcoidose + CTD-ILD connective tissue disease + EAA extrinsic allergic alveolitis + UIP usual interstitial pneumonia HRCT padr\u00e3o; (b) anti-fibr\u00f3tico<\/strong> com nintedanib Ofev Boehringer Ingelheim 150mg BID + pirfenidona Esbriet Roche 2.403mg\/d + redu\u00e7\u00e3o decl\u00ednio FVC 50% INPULSIS+ASCEND + SENSCIS PF-ILD + INBUILD; (c) SAOS apneia obstrutiva<\/strong> com AHI Apnea-Hypopnea Index \u22655 leve \/ 15-30 moderado \/ \u226530 severo + Epworth Sleepiness Scale + STOP-BANG question\u00e1rio + polissonografia tipo I-IV; (d) CPAP Continuous Positive Airway Pressure<\/strong> com ResMed AirSense 11+Philips DreamStation 2 + APAP auto-titrating + BiPAP bi-level + ASV adaptive servo-ventilation cardio CSA; (e) Inspire upper airway stimulation<\/strong> com Inspire Medical Systems implant\u00e1vel hipoglosso XII estimulador + alternativa CPAP-intolerante AHI 15-65 + IMD generator + sensor pleural + IPG implantable pulse generator.<\/p>\n

Cl\u00ednica com ILD+SAOS+CPAP madura escala redu\u00e7\u00e3o decl\u00ednio FVC 50%<\/strong> + previne mortalidade IPF<\/strong> + escala ades\u00e3o CPAP 60-80%<\/strong>. Conex\u00e3o com Lista C5<\/a>.<\/p>\n

Oxigenioterapia domiciliar + TX pulmonar + ECMO bridge: o est\u00e1gio terminal<\/h2>\n

A terceira camada \u00e9 O2 domiciliar+TX. Padr\u00e3o setorial inclui (a) oxigenioterapia domiciliar cont\u00ednua O2DC<\/strong> com PaO2 \u226455 mmHg ou SaO2 \u226488% repouso + concentrador stationary 5-10 LPM + portable POC + cilindro l\u00edquido + terapia LTOT long-term oxygen therapy 15+ horas\/dia; (b) VNI ventila\u00e7\u00e3o n\u00e3o-invasiva<\/strong> com BiPAP S\/T + ASV cardio + insufici\u00eancia hiperc\u00e1pnica DPOC GOLD 4 + neuromuscular ELA + DPOC overlap SAOS-DPOC + post-extuba\u00e7\u00e3o; (c) TX pulmonar<\/strong> com LAS Lung Allocation Score + crit\u00e9rios IPF + DPOC end-stage + cystic fibrosis FC + sarcoidose terminal + hipertens\u00e3o pulmonar idiop\u00e1tica + bilateral sequential vs single-lung; (d) ECMO bridge to TX<\/strong> com VV ECMO veno-venoso + Awake ECMO + Maquet Cardiohelp + Sorin S5 + ELSO Extracorporeal Life Support Organization registry + bridging 7-30 dias; (e) descarte O2+TX+ECMO<\/strong> com cilindro O2 + concentrador membrana + circuito ECMO heparinizado + bi\u00f3psia BAL + Lista C5 imuno tacrolimus+everolimus+MMF p\u00f3s-TX + saco amarelo+vermelho + identifica\u00e7\u00e3o A1+A2+B+C5+CID J96\/J84\/Z94.2.<\/p>\n

Cl\u00ednica com O2+TX+ECMO madura escala sobrevida 5y TX 60%<\/strong> + previne mortalidade list pr\u00e9-TX<\/strong> + gerencia rejei\u00e7\u00e3o CLAD<\/strong>. Conex\u00e3o com TX renal<\/a>.<\/p>\n

Tr\u00eas perfis de RSS por capacidade pneumo<\/h2>\n

Cl\u00ednica pneumo b\u00e1sica.<\/strong> 2 fluxos. Custo mensal R$ 12.000-32.000<\/strong> mas perda de biol\u00f3gico+ILD+TX.<\/p>\n

Cl\u00ednica pneumo m\u00e9dia.<\/strong> 3 fluxos. Custo mensal R$ 24.000-58.000<\/strong>, captura DPOC+asma+ILD.<\/p>\n

Cl\u00ednica pneumo completa 5 fluxos.<\/strong> DPOC+asma+ILD+SAOS+TX + integra\u00e7\u00e3o com servi\u00e7os hospitalares<\/a>. Custo mensal R$ 45.000-105.000<\/strong>, efic\u00e1cia 95%, ROI 800-2.500% via captura pneumol\u00f3gica + biol\u00f3gico T2-high + anti-fibr\u00f3tico FVC decl\u00ednio 50%.<\/p>\n

Os tr\u00eas erros que aparecem em pneumologia<\/h2>\n

O primeiro \u00e9 a subdimensionamento biol\u00f3gico Lista C5<\/strong>. Sem segrega\u00e7\u00e3o omalizumab+mepolizumab+benralizumab+dupilumab+tezepelumab+nintedanib+pirfenidona + Lista B\/C5 = n\u00e3o-conformidade ANVISA RDC 222 + risco contamina\u00e7\u00e3o cruzada + impacto financeiro.<\/p>\n

O segundo \u00e9 a mistura DPOC GOLD + asma T2 + ILD\/IPF<\/strong>. Confunde rastreabilidade etiol\u00f3gica + impossibilita biomarker eosinophil+FeNO+IgE espec\u00edfico + risco prescri\u00e7\u00e3o inadequada.<\/p>\n

O terceiro \u00e9 a falta de protocolo CPAP\/BiPAP descarte m\u00e1scara<\/strong>. Sem rastreabilidade ResMed+Philips+Inspire + manejo descarte m\u00e1scara silicone + circuito = risco contamina\u00e7\u00e3o cruzada + zero rastreabilidade.<\/p>\n

A regula\u00e7\u00e3o de RSS pneumo no Brasil est\u00e1 em fase de moderniza\u00e7\u00e3o t\u00e9cnica acelerada com pneumologia especializada como prioridade. As institui\u00e7\u00f5es que estruturam fluxos completos desde o in\u00edcio \u2014 alinhadas com calend\u00e1rio 2026 de compliance<\/a> \u2014 atravessam o crescimento sem solavanco. Para gestores que precisam alinhar com gest\u00e3o paralela industrial, o portal Seven Res\u00edduos sobre servi\u00e7os completos<\/a> traz a perspectiva integrada. A SBPT Sociedade Brasileira Pneumologia<\/a> \u00e9 refer\u00eancia t\u00e9cnica nacional.<\/p>\n

Solicite cota\u00e7\u00e3o RSS pneumo 5 fluxos completos<\/a><\/strong> \u2014 cap\u00edtulo dedicado a DPOC GOLD 2026 1-4+ABCD+LAMA tiotropium Spiriva+umeclidinium Incruse+glicopirr\u00f4nio Seebri+LABA salmeterol+formoterol+vilanterol+olodaterol+ICS budesonida+fluticasona+mometasona+triple Trelegy Ellipta+Breztri+Trimbow+roflumilast Daxas Lista C5, asma T2-high omalizumab Xolair anti-IgE+mepolizumab Nucala anti-IL-5+benralizumab Fasenra anti-IL-5R\u03b1+reslizumab Cinqair+dupilumab Dupixent anti-IL-4R\u03b1+tezepelumab Tezspire anti-TSLP+itepekimab anti-IL-33+eosinophil>300+FeNO>25ppb+IgE+periostin Lista C5, ILD IPF nintedanib Ofev Boehringer+pirfenidona Esbriet Roche+UIP+NSIP+COP+CTD-ILD+EAA+HRCT+INPULSIS+ASCEND+SENSCIS+INBUILD+FVC decl\u00ednio 50%, SAOS AHI+Epworth+STOP-BANG+ResMed AirSense+Philips DreamStation+CPAP+APAP+BiPAP+ASV+Inspire upper airway stimulation IPG, oxigenioterapia LTOT+VNI+TX pulmonar LAS+bilateral sequential+single-lung+ECMO VV+Maquet Cardiohelp+ELSO+CLAD+tacrolimus Prograf+everolimus Certican+MMF Lista C5+CID J44\/J45\/J84\/J96\/Z94.2.<\/p>\n","protected":false},"excerpt":{"rendered":"

RSS pneumo: DPOC + asma + ILD + CPAP + oxig\u00eanio + TX pulm. Veja.<\/p>\n","protected":false},"author":3,"featured_media":2229,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[3064,1422,2483,2041],"class_list":["post-2230","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-compliance-legislacao","tag-asma","tag-cpap","tag-dpoc","tag-pneumologia"],"_links":{"self":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2230","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/comments?post=2230"}],"version-history":[{"count":1,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2230\/revisions"}],"predecessor-version":[{"id":4338,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/posts\/2230\/revisions\/4338"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media\/2229"}],"wp:attachment":[{"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/media?parent=2230"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/categories?post=2230"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sevenresiduosaude.com.br\/blog\/wp-json\/wp\/v2\/tags?post=2230"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}